This trial is testing a new cancer drug, APG-115, to see if it is safe and effective at treating T-PLL. The study will enroll 24-36 patients.
- T-Cell Prolymphocytic Leukemia
2 Primary · 0 Secondary · Reporting Duration: 28 days
2 Treatment Groups
1 of 2
APG-115 + APG-2575 combination
1 of 2
36 Total Participants · 2 Treatment Groups
Primary Treatment: APG-115 · No Placebo Group · Phase 2
Who is running the clinical trial?
Age 18+ · All Participants · 13 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Does the APG-115 drug have governmental approval for use?
"While there is some data suggesting that APG-115 is safe, it only received a 2 because there is no evidence yet that the medication is effective." - Anonymous Online Contributor
Are new patients still being sought for this experiment?
"The data on clinicaltrials.gov does indicate that this clinical trial is currently recruiting participants. The trial was initially posted on 7/12/2021 and was most recently edited on 7/8/2022. The clinical trial is enrolling 36 patients across 3 locations." - Anonymous Online Contributor